The intranasal administration of a PamCys2 or Adjuplex has demonstrated capacity for producing protective influenza-specific lung CD8+ TRM in similar numbers and IFN-γ secreting potential when compared to the natural response to influenza infection (54, 55). The gene discussed is CD8A; the disease is influenza.